Dr. Otto Placik discusses the role of Alloclae as a non-surgical regenerative solution for breast cleavage enhancement, softening implant outlines, and hip dip correction.

Chicago, Illinois, United States, 27th Jan 2026 – Dr. Otto J. Placik, board-certified plastic surgeon and founder of BodySculptor.com, was recently featured on WGN News discussing the innovative role of Alloclae (AloeClae structured adipose matrices) in plastic surgery. The segment focused on how this regenerative technology is being used for isolated, non-surgical enhancement of breast cleavage, softening of breast implant outlines, correction of hip dips, and treatment of contour irregularities, without conventional surgery.

Alloclae is not a mommy makeover or surgical procedure. It is a non-surgical regenerative treatment designed to be used independently for targeted aesthetic correction.

Dr. Placik is the first board-certified plastic surgeon in Illinois to offer the Alloclae procedure, making his practice the earliest board-certified provider of this technology in the state. His practice is widely recognized as home to the top plastic surgeon in Illinois and top plastic surgeon in Chicago, a distinction that continues to draw patients seeking the most advanced aesthetic care.

The WGN News feature introduced Alloclae as a biostimulatory option designed to complement the body’s natural tissue response and restore soft volume in areas that traditionally required surgery.

Modern Mommy Makeover: A Regenerative Surgical Approach

In today’s aesthetic landscape, the Modern Mommy Makeover represents a regenerative surgical approach to body rejuvenation that centers on natural, restorative transformation. Unlike traditional methods that rely exclusively on implants, this approach incorporates autogenous (self-derived) tissue and biostimulatory materials.

Alloclae is not part of the mommy makeover procedure and is not a surgical solution. It is offered separately as a non-surgical regenerative treatment for patients who do not wish to undergo surgery.

Developed by board-certified plastic surgeon Dr. Otto J. Placik, the Modern Mommy Makeover combines surgical precision with regenerative science. The goal is to restore proportion and confidence while maintaining a natural aesthetic.

Natural Chest Enhancement with Autogenous Fat Transfer

A central component of the surgical approach is autogenous fat transfer, which uses a patient’s own fat for breast enhancement without implants. Fat is harvested from areas such as the abdomen, waist, or thighs, purified, and transferred to the chest to restore volume and shape.

This method provides:

• Use of self-derived tissue
• Biostimulatory regenerative response
• Long-term structural support through modern fat-processing techniques

For patients seeking subtle refinement, fat transfer may also be combined with a lift or a small implant to maintain balance and proportion.

Sculpting Beyond the Waistline

The Modern Mommy Makeover also incorporates regenerative contouring beyond the chest. Autogenous fat can be transferred to areas such as the hips, buttocks, and hip dips to enhance symmetry and proportion.

For patients who do not wish to undergo surgery or do not have sufficient donor fat, Alloclae is offered separately as a non-surgical biostimulatory alternative for hip dip correction and contour smoothing.

Modern Implant Solutions for Active Patients

For patients who choose implants, modern designs such as Motiva SmoothSilk® implants feature advanced biocompatibility and smooth surfaces. These implants are placed pre-pectorally (over the muscle) to preserve chest strength, reduce discomfort, and maintain flexibility.

Enhanced Recovery and Minimal Scarring

The Modern Mommy Makeover emphasizes regenerative recovery through:

• Multi-layered closure techniques
• Advanced anesthesia protocols
• Accelerated recovery pathways

These methods are designed to support healing, reduce downtime, and minimize visible scarring.

Labiaplasty and Intimate Wellness Integration

The Modern Mommy Makeover may also include labiaplasty and vaginal rejuvenation. Dr. Placik is a recognized labiaplasty specialist in Chicago and integrates these procedures when desired.

Regenerative fat injections or fillers may be used to restore the outer labia, and vaginoplasty may be included for functional concerns.

A Regenerative Standard in Aesthetic Surgery

Each element of the Modern Mommy Makeover reflects a regenerative philosophy based on restoration through the body’s own biological processes. Whether using autogenous fat, biostimulatory materials, or restorative closure methods, the approach emphasizes renewal rather than replacement.

What Patients Should Know Before Choosing a Modern Mommy Makeover

For those considering a Modern Mommy Makeover, reviewing before-and-after photos that show results at least one year post-procedure can provide insight into long-term outcomes.

Incisions are designed low and curved, typically hidden beneath underwear or swimwear. 

Sculpting often includes 360° liposuction, flank and back contouring, and rib-area sculpting.

Muscle tightening is commonly included through internal repair techniques.

A Regenerative Path Forward

The Modern Mommy Makeover reflects a regenerative philosophy that prioritizes natural restoration through autogenous tissue and restorative surgical methods.

Through this regenerative framework, Dr. Otto Placik, the first board-certified plastic surgeon in Illinois to offer Alloclae and widely recognized as a top plastic surgeon in Chicago and Illinois, continues to advance both surgical and non-surgical regenerative solutions at BodySculptor.com.

For updates, follow Dr. Otto Placik on Instagram:

https://www.instagram.com/drplacik/

WGN News segment:

https://wgntv.com/daytime-chicago/what-is-alloclae/

More information about Alloclae:

https://bodysculptor.com/non-surgical/alloclae-adipose-filler/

Media Contact

Organization: Associated Plastic Surgeons, SC: Practice of Otto J Placik MD, FACS

Contact Person: Otto J. Placik, MD, FACS

Website: https://www.instagram.com/drplacik

Email: Send Email

City: Chicago

State: Illinois

Country:United States

Release id:40636

The post Top Plastic Surgeon Chicago Dr. Otto Placik Showcases Alloclae Innovation on WGN News appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.

Transcranial Magnetic Stimulation, commonly known as TMS, is a non-invasive procedure that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, TMS has been studied extensively and incorporated into treatment guidelines in several countries for individuals with major depressive disorder, particularly where symptoms have persisted despite standard treatment approaches.

The expanded access initiative follows increased clinical interest in treatment pathways that complement existing mental health care models. Depression remains a significant public health concern, with many individuals experiencing ongoing symptoms that affect daily functioning, work participation, and quality of life. In response, mental health services continue to explore a broader range of evidence-based interventions that can be delivered safely and effectively under medical supervision.

Dr Shanek Wick, Medical Director at Neuralia TMS, said the expansion reflects a focus on improving availability of established neuromodulation therapies for appropriate patients. “Transcranial Magnetic Stimulation is a non-invasive treatment option that has been supported by a growing body of clinical research for the management of depression,” Dr Wick said. “Broadening access allows more individuals to be assessed for suitability within a structured medical framework.”

Neuralia TMS provides TMS therapy as part of a comprehensive clinical assessment process, ensuring that treatment plans are informed by individual health history and current clinical needs. Sessions are typically delivered over a course of scheduled appointments, allowing patients to continue with usual daily activities during treatment. Reported side effects are generally mild and temporary, most commonly including scalp discomfort or headache during early sessions.

In addition to depression-focused care, Neuralia TMS offers neuromodulation services for a range of neurological and psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home neuromodulation therapy delivered under clinical guidance, and pharmacogenetic testing to support personalised treatment planning based on genetic factors. These services are integrated into broader care considerations rather than positioned as replacements for established mental health treatments.

The expansion of TMS access aligns with wider trends in mental health care that emphasise individualised treatment planning and multidisciplinary approaches. Clinicians increasingly recognise that effective management of depression often involves combining multiple evidence-based strategies, including psychological therapies, medication, and non-invasive interventions. Neuromodulation therapies are being considered as part of this broader continuum of care.

Health sector observers note that non-invasive brain stimulation continues to attract attention as research into brain function and mental health advances. Ongoing clinical studies are exploring how treatment protocols may be refined and how outcomes can be better predicted across different patient groups. Within this context, careful clinical oversight and adherence to established standards remain central to responsible implementation.

Dr Wick said continued evaluation and clinical development will remain important as the field evolves. “Future directions in neuromodulation are expected to involve more precise targeting, improved individualisation of treatment protocols, and closer integration with other mental health services,” Dr Wick said. “Ongoing research and clinical review will play an important role in guiding how these therapies are applied over time.”

Neuralia TMS stated that all patients undergo a comprehensive medical assessment to determine whether TMS is clinically appropriate. The clinic operates in accordance with established medical and professional standards, with an emphasis on informed decision-making and patient safety.

The announcement comes amid continued public discussion about access to timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS aims to contribute to the availability of additional clinical options for individuals and referring practitioners seeking alternatives within a medically supervised setting.

For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au. 

Media Contact

Organization: Neuralia TMS

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +61862303996

Country:Australia

Release id:40609

Disclaimer: This announcement is provided for general informational purposes only and does not constitute medical advice. Transcranial Magnetic Stimulation suitability and outcomes vary by individual and should be determined through assessment by a qualified medical professional.

The post Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Australia, 27th Jan 2026 – Neuralia TMS, a respected provider of non-invasive neuromodulation therapies, has announced an expansion of access to Transcranial Magnetic Stimulation treatment for individuals living with depression, reflecting continued developments in evidence-based mental health care and increasing demand for non-pharmacological treatment options. The expanded availability is intended to support patients seeking additional clinical pathways under medical supervision.

Transcranial Magnetic Stimulation, commonly known as TMS, is a non-invasive procedure that uses targeted magnetic pulses to stimulate specific areas of the brain associated with mood regulation. The treatment does not involve medication or surgery and is delivered in an outpatient setting. Over the past two decades, TMS has been studied extensively and incorporated into treatment guidelines in several countries for individuals with major depressive disorder, particularly where symptoms have persisted despite standard treatment approaches.

The expanded access initiative follows increased clinical interest in treatment pathways that complement existing mental health care models. Depression remains a significant public health concern, with many individuals experiencing ongoing symptoms that affect daily functioning, work participation, and quality of life. In response, mental health services continue to explore a broader range of evidence-based interventions that can be delivered safely and effectively under medical supervision.

Dr Shanek Wick, Medical Director at Neuralia TMS, said the expansion reflects a focus on improving availability of established neuromodulation therapies for appropriate patients. “Transcranial Magnetic Stimulation is a non-invasive treatment option that has been supported by a growing body of clinical research for the management of depression,” Dr Wick said. “Broadening access allows more individuals to be assessed for suitability within a structured medical framework.”

Neuralia TMS provides TMS therapy as part of a comprehensive clinical assessment process, ensuring that treatment plans are informed by individual health history and current clinical needs. Sessions are typically delivered over a course of scheduled appointments, allowing patients to continue with usual daily activities during treatment. Reported side effects are generally mild and temporary, most commonly including scalp discomfort or headache during early sessions.

In addition to depression-focused care, Neuralia TMS offers neuromodulation services for a range of neurological and psychiatric conditions, including anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, chronic pain, and Parkinson’s disease. The clinic also provides transcranial Direct Current Stimulation, an at-home neuromodulation therapy delivered under clinical guidance, and pharmacogenetic testing to support personalised treatment planning based on genetic factors. These services are integrated into broader care considerations rather than positioned as replacements for established mental health treatments.

The expansion of TMS access aligns with wider trends in mental health care that emphasise individualised treatment planning and multidisciplinary approaches. Clinicians increasingly recognise that effective management of depression often involves combining multiple evidence-based strategies, including psychological therapies, medication, and non-invasive interventions. Neuromodulation therapies are being considered as part of this broader continuum of care.

Health sector observers note that non-invasive brain stimulation continues to attract attention as research into brain function and mental health advances. Ongoing clinical studies are exploring how treatment protocols may be refined and how outcomes can be better predicted across different patient groups. Within this context, careful clinical oversight and adherence to established standards remain central to responsible implementation.

Dr Wick said continued evaluation and clinical development will remain important as the field evolves. “Future directions in neuromodulation are expected to involve more precise targeting, improved individualisation of treatment protocols, and closer integration with other mental health services,” Dr Wick said. “Ongoing research and clinical review will play an important role in guiding how these therapies are applied over time.”

Neuralia TMS stated that all patients undergo a comprehensive medical assessment to determine whether TMS is clinically appropriate. The clinic operates in accordance with established medical and professional standards, with an emphasis on informed decision-making and patient safety.

The announcement comes amid continued public discussion about access to timely and evidence-based mental health care. By expanding access to non-invasive TMS treatment for depression, Neuralia TMS aims to contribute to the availability of additional clinical options for individuals and referring practitioners seeking alternatives within a medically supervised setting.

For further information regarding the expanded access to TMS treatment for depression, media enquiries may be directed to Neuralia TMS. The clinic can be contacted by phone on 08 6230 3996 or via email at info@neuralia.com.au. 

Media Contact

Organization: Neuralia TMS

Contact Person: Dr Shanek Wick

Website: https://www.neuraliatms.com.au/

Email: Send Email

Contact Number: +61862303996

Country:Australia

Release id:40609

Disclaimer: This announcement is provided for general informational purposes only and does not constitute medical advice. Transcranial Magnetic Stimulation suitability and outcomes vary by individual and should be determined through assessment by a qualified medical professional.

The post Neuralia TMS Broadens Access to Non-Invasive TMS Treatment for Depression appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section